Rather than ethical or rogue, the stem cell therapy field is a complex grey area.
Wealth conditions the affordability of standards and stem cell strategies.
Governments create different regulatory spaces for experimental research.
Regulation for stem cell therapies can be designed to gain a competitive edge.
Local and global stem cell organisations resist and undermine dominant ones.